RU2004105956A - Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. - Google Patents
Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. Download PDFInfo
- Publication number
- RU2004105956A RU2004105956A RU2004105956/04A RU2004105956A RU2004105956A RU 2004105956 A RU2004105956 A RU 2004105956A RU 2004105956/04 A RU2004105956/04 A RU 2004105956/04A RU 2004105956 A RU2004105956 A RU 2004105956A RU 2004105956 A RU2004105956 A RU 2004105956A
- Authority
- RU
- Russia
- Prior art keywords
- allyloxy
- bis
- acetic acid
- phenyl
- chlorophenyl
- Prior art date
Links
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 90
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 80
- 125000005336 allyloxy group Chemical group 0.000 claims 78
- -1 hydroxy, cyano, amino Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 43
- 235000019260 propionic acid Nutrition 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 28
- 150000002367 halogens Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 8
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 8
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005110 aryl thio group Chemical group 0.000 claims 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108020004017 nuclear receptors Proteins 0.000 claims 3
- 102000006255 nuclear receptors Human genes 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- XTKJJTSBXITZND-UHFFFAOYSA-N 2-[3-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OCC=C(C=2C=CC(Br)=CC=2)C=2C=CC(Br)=CC=2)=C1 XTKJJTSBXITZND-UHFFFAOYSA-N 0.000 claims 2
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- ZNPVUJSNQYBLAG-GHRIWEEISA-N 2-[3-[(e)-3-[4-(4-bromophenyl)phenyl]but-2-enoxy]phenyl]acetic acid Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(/C)=C/COC1=CC=CC(CC(O)=O)=C1 ZNPVUJSNQYBLAG-GHRIWEEISA-N 0.000 claims 1
- KNIDRVOZXCMHTL-NTEUORMPSA-N 2-[3-chloro-4-[(e)-3-(2-phenyl-1,3-thiazol-5-yl)but-2-enoxy]phenyl]acetic acid Chemical compound C=1N=C(C=2C=CC=CC=2)SC=1C(/C)=C/COC1=CC=C(CC(O)=O)C=C1Cl KNIDRVOZXCMHTL-NTEUORMPSA-N 0.000 claims 1
- KNIDRVOZXCMHTL-ZROIWOOFSA-N 2-[3-chloro-4-[(z)-3-(2-phenyl-1,3-thiazol-5-yl)but-2-enoxy]phenyl]acetic acid Chemical compound C=1N=C(C=2C=CC=CC=2)SC=1C(/C)=C\COC1=CC=C(CC(O)=O)C=C1Cl KNIDRVOZXCMHTL-ZROIWOOFSA-N 0.000 claims 1
- XQSQXTITVLEPEC-HYARGMPZSA-N 2-[4-[(e)-3-(4-bromophenyl)-3-phenylprop-2-enoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC\C=C(C=1C=CC(Br)=CC=1)/C1=CC=CC=C1 XQSQXTITVLEPEC-HYARGMPZSA-N 0.000 claims 1
- OIHKRDDGCUUDRN-OBGWFSINSA-N 2-[4-[(e)-3-(4-phenoxyphenyl)but-2-enoxy]phenyl]acetic acid Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(/C)=C/COC1=CC=C(CC(O)=O)C=C1 OIHKRDDGCUUDRN-OBGWFSINSA-N 0.000 claims 1
- ZNUMPCVQIBHZOC-SFQUDFHCSA-N 2-[4-[(e)-3-(9h-fluoren-2-yl)but-2-enoxy]phenyl]acetic acid Chemical compound C=1C=C(C2=CC=CC=C2C2)C2=CC=1C(/C)=C/COC1=CC=C(CC(O)=O)C=C1 ZNUMPCVQIBHZOC-SFQUDFHCSA-N 0.000 claims 1
- KFLOAWUJCIVKIB-GHRIWEEISA-N 2-[4-[(e)-3-(9h-fluoren-2-yl)but-2-enoxy]phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1OC\C=C(/C)C1=CC=C2C3=CC=CC=C3CC2=C1 KFLOAWUJCIVKIB-GHRIWEEISA-N 0.000 claims 1
- YYFMGAIRBHSELC-SAPNQHFASA-N 2-[4-[(e)-3-[4-(4-bromophenyl)phenyl]but-2-enoxy]phenyl]acetic acid Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(/C)=C/COC1=CC=C(CC(O)=O)C=C1 YYFMGAIRBHSELC-SAPNQHFASA-N 0.000 claims 1
- ONOWLZHMISYVLA-UHFFFAOYSA-N 2-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]-3-chlorophenyl]acetic acid Chemical compound ClC1=CC(CC(=O)O)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 ONOWLZHMISYVLA-UHFFFAOYSA-N 0.000 claims 1
- AHVHHKDNTFMYLW-UHFFFAOYSA-N 2-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 AHVHHKDNTFMYLW-UHFFFAOYSA-N 0.000 claims 1
- PKQSISYCYNVSDW-UHFFFAOYSA-N 3-[3-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=CC(OCC=C(C=2C=CC(Br)=CC=2)C=2C=CC(Br)=CC=2)=C1 PKQSISYCYNVSDW-UHFFFAOYSA-N 0.000 claims 1
- JWIAPHNMDBEPFB-UHFFFAOYSA-N 3-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 JWIAPHNMDBEPFB-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- OYVPVQDEWVWBME-XDJHFCHBSA-N ethyl 2-[3-[(e)-3-[4-(4-bromophenyl)phenyl]but-2-enoxy]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(OC\C=C(/C)C=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=C1 OYVPVQDEWVWBME-XDJHFCHBSA-N 0.000 claims 1
- ALFXBJDOIWDDKJ-LFIBNONCSA-N ethyl 2-[3-chloro-4-[(e)-3-(2-phenyl-1,3-thiazol-5-yl)but-2-enoxy]phenyl]acetate Chemical compound ClC1=CC(CC(=O)OCC)=CC=C1OC\C=C(/C)C1=CN=C(C=2C=CC=CC=2)S1 ALFXBJDOIWDDKJ-LFIBNONCSA-N 0.000 claims 1
- ALFXBJDOIWDDKJ-WJDWOHSUSA-N ethyl 2-[3-chloro-4-[(z)-3-(2-phenyl-1,3-thiazol-5-yl)but-2-enoxy]phenyl]acetate Chemical compound ClC1=CC(CC(=O)OCC)=CC=C1OC\C=C(\C)C1=CN=C(C=2C=CC=CC=2)S1 ALFXBJDOIWDDKJ-WJDWOHSUSA-N 0.000 claims 1
- YFAOKTXJXYDRHM-HYARGMPZSA-N ethyl 2-[4-[(e)-3-(4-bromophenyl)-3-phenylprop-2-enoxy]-3-chlorophenyl]acetate Chemical compound ClC1=CC(CC(=O)OCC)=CC=C1OC\C=C(C=1C=CC(Br)=CC=1)/C1=CC=CC=C1 YFAOKTXJXYDRHM-HYARGMPZSA-N 0.000 claims 1
- XXRLTBVKUDTBDJ-XDJHFCHBSA-N ethyl 2-[4-[(e)-3-(9h-fluoren-2-yl)but-2-enoxy]phenyl]propanoate Chemical compound C1=CC(C(C)C(=O)OCC)=CC=C1OC\C=C(/C)C1=CC=C2C3=CC=CC=C3CC2=C1 XXRLTBVKUDTBDJ-XDJHFCHBSA-N 0.000 claims 1
- VUUKCQZVJBXDCB-UHFFFAOYSA-N ethyl 2-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]-3-chlorophenyl]acetate Chemical compound ClC1=CC(CC(=O)OCC)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 VUUKCQZVJBXDCB-UHFFFAOYSA-N 0.000 claims 1
- JPZZOCRNTVCBAQ-UHFFFAOYSA-N ethyl 3-[3-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(OCC=C(C=2C=CC(Br)=CC=2)C=2C=CC(Br)=CC=2)=C1 JPZZOCRNTVCBAQ-UHFFFAOYSA-N 0.000 claims 1
- NQWYIAKDFJEQFQ-UHFFFAOYSA-N ethyl 3-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OCC)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 NQWYIAKDFJEQFQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- DXEQCGCXFPJYAK-HZHRSRAPSA-N methyl 2-[4-[(e)-3-(4-bromophenyl)-3-phenylprop-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OC\C=C(C=1C=CC(Br)=CC=1)/C1=CC=CC=C1 DXEQCGCXFPJYAK-HZHRSRAPSA-N 0.000 claims 1
- BALHWYJTFQLDSV-KNTRCKAVSA-N methyl 2-[4-[(e)-3-(4-phenoxyphenyl)but-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OC\C=C(/C)C(C=C1)=CC=C1OC1=CC=CC=C1 BALHWYJTFQLDSV-KNTRCKAVSA-N 0.000 claims 1
- QUJDKESJCPQXCF-QGOAFFKASA-N methyl 2-[4-[(e)-3-(9h-fluoren-2-yl)but-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OC\C=C(/C)C1=CC=C2C3=CC=CC=C3CC2=C1 QUJDKESJCPQXCF-QGOAFFKASA-N 0.000 claims 1
- UZQHMNZKDCELTO-OBGWFSINSA-N methyl 2-[4-[(e)-3-[4-(4-bromophenyl)phenyl]but-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OC\C=C(/C)C1=CC=C(C=2C=CC(Br)=CC=2)C=C1 UZQHMNZKDCELTO-OBGWFSINSA-N 0.000 claims 1
- DXEQCGCXFPJYAK-HAHDFKILSA-N methyl 2-[4-[(z)-3-(4-bromophenyl)-3-phenylprop-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OC\C=C(C=1C=CC(Br)=CC=1)\C1=CC=CC=C1 DXEQCGCXFPJYAK-HAHDFKILSA-N 0.000 claims 1
- OTTRYSUIFFPDED-UHFFFAOYSA-N methyl 2-[4-[3,3-bis(4-bromophenyl)prop-2-enoxy]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OCC=C(C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 OTTRYSUIFFPDED-UHFFFAOYSA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101154 | 2001-07-30 | ||
| DKPA200101154 | 2001-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004105956A true RU2004105956A (ru) | 2005-03-27 |
Family
ID=8160643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004105956/04A RU2004105956A (ru) | 2001-07-30 | 2002-07-05 | Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1414778A1 (cs) |
| JP (1) | JP2004536150A (cs) |
| KR (1) | KR20040019087A (cs) |
| CN (1) | CN1537093A (cs) |
| BR (1) | BR0211414A (cs) |
| CA (1) | CA2452665A1 (cs) |
| CZ (1) | CZ2004133A3 (cs) |
| HU (1) | HUP0401575A2 (cs) |
| IL (1) | IL159547A0 (cs) |
| MX (1) | MXPA04000891A (cs) |
| NO (1) | NO20040389L (cs) |
| PL (1) | PL366401A1 (cs) |
| RU (1) | RU2004105956A (cs) |
| WO (1) | WO2003011807A1 (cs) |
| ZA (1) | ZA200400161B (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412935C2 (ru) * | 2005-06-30 | 2011-02-27 | Хай Пойнт Фармасьютикалс, ЛЛС | Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022533A1 (en) * | 2002-09-05 | 2004-03-18 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
| CA2503276A1 (en) * | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds useful in treating ppar mediated diseases |
| BR0315683A (pt) * | 2002-10-28 | 2005-08-30 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade |
| WO2004087053A2 (en) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| ITRM20030305A1 (it) * | 2003-06-20 | 2004-12-21 | Sigma Tau Ind Farmaceuti | Preparazione di nuovi derivati di acidi fenil o fenossialchil mono e dicarbossilici utili nel trattamento dell'iperglicemia e dell'ipertrigliceridemia tipiche del diabete del tipo ii. |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| SG145752A1 (en) * | 2003-09-19 | 2008-09-29 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| DK1670744T5 (da) * | 2003-09-19 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-((Phenoxyalkyl)-thio)-phenoxyeddikesyrer og analoge |
| US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
| CA2631390C (en) * | 2005-12-22 | 2014-03-11 | Per Sauerberg | Phenoxy acetic acids as ppar delta activators |
| PE20080188A1 (es) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
| KR100693132B1 (ko) * | 2006-06-23 | 2007-03-14 | 동해전장 주식회사 | 정션박스내에 삽입된 릴레이의 동작 검사 장치 |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US20120168303A1 (en) * | 2011-01-05 | 2012-07-05 | Sueng-Nien Kao | Salt water activated emergency lighting device |
| CN103467408B (zh) * | 2013-09-03 | 2015-01-21 | 浙江医药高等专科学校 | 一类四氮唑羧酸类化合物及其用途 |
| CN103467406B (zh) * | 2013-09-03 | 2014-12-17 | 浙江医药高等专科学校 | 卤素取代的四氮唑羧酸类化合物、其制备方法和用途 |
| CN103467407B (zh) * | 2013-09-03 | 2015-04-22 | 浙江医药高等专科学校 | 四氮唑羧酸类化合物及其用途 |
| CN103467405B (zh) * | 2013-09-03 | 2015-01-07 | 浙江医药高等专科学校 | 一类四氮唑羧酸类化合物、其制备方法和用途 |
| CN103467409B (zh) * | 2013-09-03 | 2015-01-07 | 浙江医药高等专科学校 | 取代的四氮唑羧酸类化合物及其用途 |
| WO2022020376A1 (en) | 2020-07-22 | 2022-01-27 | Reneo Pharmaceuticals, Inc. | Crystalline ppar-delta agonist |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3373467D1 (en) * | 1982-06-14 | 1987-10-15 | Takeda Chemical Industries Ltd | Vinyl carboxylic acid derivatives, their production and use |
| AU2652397A (en) * | 1996-05-13 | 1997-12-05 | Nippon Shinyaku Co. Ltd. | Substituted ethylene compounds and drugs |
| CA2367356A1 (en) * | 1999-04-20 | 2000-10-26 | Per Sauerberg | New compounds, their preparation and use |
| EP1254101A1 (en) * | 2000-01-28 | 2002-11-06 | Novo Nordisk A/S | Propionic acid derivatives and their use in the treatment of diabetes and obesity |
-
2002
- 2002-07-05 JP JP2003517001A patent/JP2004536150A/ja active Pending
- 2002-07-05 WO PCT/DK2002/000471 patent/WO2003011807A1/en not_active Ceased
- 2002-07-05 RU RU2004105956/04A patent/RU2004105956A/ru not_active Application Discontinuation
- 2002-07-05 HU HU0401575A patent/HUP0401575A2/hu unknown
- 2002-07-05 PL PL02366401A patent/PL366401A1/xx not_active Application Discontinuation
- 2002-07-05 MX MXPA04000891A patent/MXPA04000891A/es unknown
- 2002-07-05 IL IL15954702A patent/IL159547A0/xx unknown
- 2002-07-05 BR BR0211414-3A patent/BR0211414A/pt not_active IP Right Cessation
- 2002-07-05 CA CA002452665A patent/CA2452665A1/en not_active Abandoned
- 2002-07-05 CZ CZ2004133A patent/CZ2004133A3/cs unknown
- 2002-07-05 CN CNA028150996A patent/CN1537093A/zh active Pending
- 2002-07-05 KR KR10-2004-7001417A patent/KR20040019087A/ko not_active Withdrawn
- 2002-07-05 EP EP02745186A patent/EP1414778A1/en not_active Withdrawn
-
2004
- 2004-01-09 ZA ZA200400161A patent/ZA200400161B/en unknown
- 2004-01-29 NO NO20040389A patent/NO20040389L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412935C2 (ru) * | 2005-06-30 | 2011-02-27 | Хай Пойнт Фармасьютикалс, ЛЛС | Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar |
Also Published As
| Publication number | Publication date |
|---|---|
| PL366401A1 (en) | 2005-01-24 |
| KR20040019087A (ko) | 2004-03-04 |
| CN1537093A (zh) | 2004-10-13 |
| BR0211414A (pt) | 2004-08-17 |
| NO20040389L (no) | 2004-01-29 |
| MXPA04000891A (es) | 2004-05-21 |
| CZ2004133A3 (cs) | 2004-06-16 |
| HUP0401575A2 (hu) | 2004-11-29 |
| JP2004536150A (ja) | 2004-12-02 |
| CA2452665A1 (en) | 2003-02-13 |
| EP1414778A1 (en) | 2004-05-06 |
| ZA200400161B (en) | 2004-08-18 |
| IL159547A0 (en) | 2004-06-01 |
| WO2003011807A1 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004105956A (ru) | Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. | |
| RU2001131111A (ru) | Новые соединения, их получение и применение | |
| DK2278960T3 (en) | DOSAGE regimen for a selective SIP1 RECEPTOR AGONIST | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| JP2009531280A5 (cs) | ||
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2009537559A5 (cs) | ||
| RU2004114875A (ru) | Производные дикарбоновых кислот, их получение и терапевтическое применение | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| RU2008123000A (ru) | Соединения для лечения метаболических нарушений | |
| RU2003121236A (ru) | Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием | |
| CA2521589A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2502297A1 (en) | Compounds for the treatment of metabolic disorders | |
| RU2005109555A (ru) | Новые производные винилкарбоновой кислоты и их терапевтическое применение | |
| WO2013079407A1 (en) | Aryl derivatives for controlling ectoparasites | |
| US20080051321A1 (en) | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | |
| RU2006108572A (ru) | Соединения для лечения метаболических нарушений | |
| KR100608416B1 (ko) | 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체 | |
| RU2005116243A (ru) | Новые соединения и их применение в качестве ppar-модуляторов | |
| JP2008530242A5 (cs) | ||
| RU2005116256A (ru) | Новые соединения, применимые при лечении ppar опосредованных заболеваний | |
| JPWO2020047447A5 (cs) | ||
| CN100339073C (zh) | 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺 | |
| JP2004532267A5 (cs) | ||
| JP2009524686A5 (cs) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060728 |